Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2016, Article ID 7407153, 8 pages
http://dx.doi.org/10.1155/2016/7407153
Clinical Study

Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR

1Department of Cardiology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
2Department of Medicine, Gansu Provincial Hospital of TCM, Lanzhou 730050, China
3Department of Cardiology, Xi’an Central Hospital, Xi’an 710003, China

Received 23 December 2015; Revised 11 April 2016; Accepted 16 May 2016

Academic Editor: Alexander N. Orekhov

Copyright © 2016 Zhongxia Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. J. Wilson, G. Nakazawa, R. S. Schwartz et al., “Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries,” Circulation, vol. 120, no. 2, pp. 141–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. V. Finn, G. Nakazawa, M. Joner et al., “Vascular responses to drug eluting stents: importance of delayed healing,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 7, pp. 1500–1510, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Joner, K. Morimoto, H. Kasukawa et al., “Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 11, pp. 1960–1966, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Liu, X.-Z. Zhuo, W. Liu et al., “Drug-eluting stent, but not bare metal stent, accentuates the systematic inflammatory response in patients,” Cardiology, vol. 128, no. 3, pp. 259–265, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Wu, W. Zhang, W. Liu, X. Zhuo, Z. Zhao, and Z. Yuan, “The double-faced metabolic and inflammatory effects of standard drug therapy in patients after percutaneous treatment with drug-eluting stent,” Atherosclerosis, vol. 215, no. 1, pp. 170–175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. W.-S. Lee and J. Kim, “Peroxisome proliferator-activated receptors and the heart: lessons from the past and future directions,” PPAR Research, vol. 2015, Article ID 271983, 18 pages, 2015. View at Publisher · View at Google Scholar
  7. R. B. Clark, D. Bishop-Bailey, T. Estrada-Hernandez, T. Hla, L. Puddington, and S. J. Padula, “The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses,” Journal of Immunology, vol. 164, no. 3, pp. 1364–1371, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Cuzzocrea, B. Pisano, L. Dugo et al., “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation,” European Journal of Pharmacology, vol. 483, no. 1, pp. 79–93, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ricote, J. Huang, L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells,” Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. Chen, S. Ishibashi, S. Perrey et al., “Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 372–377, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. A. R. Collins, W. P. Meehan, U. Kintscher et al., “Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 365–371, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. J. A. Dormandy, B. Charbonnel, D. J. A. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen, “Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials,” The Journal of the American Medical Association, vol. 298, no. 10, pp. 1180–1188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Thorp, G. Kuriakose, Y. M. Shah, F. J. Gonzalez, and I. Tabas, “Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice,” Circulation, vol. 116, no. 19, pp. 2182–2190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Peng, Y. Huan, Q. Jiang, S.-J. Sun, C.-M. Jia, and Z.-F. Shen, “Effects and potential mechanisms of pioglitazone on lipid metabolism in obese diabetic KKAy mice,” PPAR Research, vol. 2014, Article ID 538183, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Nylænde, A. Kroese, E. Stranden et al., “Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease,” Vascular Medicine, vol. 11, no. 1, pp. 21–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Marx, J. Wöhrle, T. Nusser et al., “Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients,” Circulation, vol. 112, no. 18, pp. 2792–2798, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Nakazawa, A. V. Finn, M. Joner et al., “Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study,” Circulation, vol. 118, no. 11, pp. 1138–1145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Virmani, G. Guagliumi, A. Farb et al., “Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?” Circulation, vol. 109, no. 6, pp. 701–705, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Császár, “Anti-atherosclerotic effect of pioglitazone—the first evidence of the role of triglyceride/HDL ratio,” Lege Artis Medicinae, vol. 21, no. 2, pp. 105–111, 2011. View at Google Scholar · View at Scopus
  23. K. J. Waite, Z. E. Floyd, P. Arbour-Reily, and J. M. Stephens, “Interferon-γ-induced regulation of peroxisome proliferator-activated receptor γ and STATs in adipocytes,” Journal of Biological Chemistry, vol. 276, no. 10, pp. 7062–7068, 2001. View at Publisher · View at Google Scholar · View at Scopus